{"filings":[{"id":1415077,"accession_number":"0001193125-26-294507","cik":863894,"company_name":"VERU INC.","ticker":"VERU","form_type":"8-K","filed_at":"2026-07-02T20:08:22+00:00","items":["1.01","9.01"],"status":"ready","headline":"Veru enters $21.8M at-the-market equity offering with Oppenheimer and Canaccord","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $21.8M of common stock may be sold from time to time via ATM offering.","Sales agents: Oppenheimer & Co. Inc. and Canaccord Genuity LLC; commission 3.0% of gross proceeds.","Shares registered under existing S-3 (File No. 333-294911) effective April 15, 2026.","Company is not obligated to sell any shares; each sale subject to placement notice.","Proceeds for general corporate purposes; no specific use stated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":33870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":843642,"accession_number":"0001437749-26-019478","cik":863894,"company_name":"VERU INC.","ticker":"VERU","form_type":"8-K","filed_at":"2026-06-04T12:30:11+00:00","items":["8.01"],"status":"ready","headline":"Veru enters clinical supply deal with Novo Nordisk for Phase 2b combo study of enobosarm + Wegovy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Veru sponsors Phase 2b PLATEAU study testing enobosarm + Wegovy in older adults with obesity on GLP-1 therapy.","Novo Nordisk supplies Wegovy at no cost; Veru retains full global rights to enobosarm.","Veru grants Novo Nordisk right of first negotiation if Veru develops enobosarm combo with any Novo GLP-1 product.","Veru provides trial design and safety data insights; no financial terms disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":33870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":49928,"accession_number":"0001193125-26-220569","cik":863894,"company_name":"VERU INC.","ticker":"VERU","form_type":"8-K","filed_at":"2026-05-13T11:00:07+00:00","items":["2.02","9.01"],"status":"ready","headline":"Veru Q2 net loss $2.7M; PLATEAU trial interim analysis expected Q1 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $2.7M ($0.12/sh) vs $7.9M ($0.54) in Q2 2025; operating loss $7.2M.","Cash, equivalents & restricted cash $27.6M as of Mar 31, 2026, up from $15.8M Sep 30, 2025.","Phase 2b PLATEAU trial actively enrolling; interim analysis on lean/fat mass expected Q1 2027.","R&D expenses $3.1M (down from $3.9M); G&A $4.1M (down from $5.2M) vs year-ago quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":33870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115169,"accession_number":"0001437749-26-008216","cik":863894,"company_name":"VERU INC.","ticker":"VERU","form_type":"8-K","filed_at":"2026-03-13T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Veru shareholders approve 2018 Equity Incentive Plan amendment, boosting authorized shares to 5.85M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders voted to increase shares authorized under the plan from 2.6M to 5.85M (4,743,572 for, 975,452 against).","Annual award limit for non-employee directors raised from 10,000 to 120,000 shares; for other participants from 100,000 to 750,000 shares.","All six director nominees elected: Steiner, Fisch, Rankowitz, Hyun, Lu, Katzovitz (votes for ranged 5.3M to 5.5M).","Ratification of Cherry Bekaert LLP as independent auditor for FY 2026 passed (10,040,215 for, 115,840 against).","Advisory vote on named executive officer compensation approved (4,476,916 for, 735,523 against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":33870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115168,"accession_number":"0001193125-26-045527","cik":863894,"company_name":"VERU INC.","ticker":"VERU","form_type":"8-K","filed_at":"2026-02-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Veru Q1 net loss narrows to $5.3M; cash $33M; Phase 2b obesity trial on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $5.3M ($0.26 per share) vs $8.9M ($0.61) in Q1 FY2025.","Cash, cash equivalents and restricted cash increased to $33.0M from $15.8M at Sep 30, 2025.","Operating loss from continuing operations improved to $5.4M from $10.2M.","Phase 2b PLATEAU trial of enobosarm+semaglutide in obesity to start Q1 2026; interim analysis Q1 2027.","R&D spend fell to $1.3M from $5.7M; G&A to $4.1M from $5.2M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":33870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131585,"accession_number":"0001193125-25-321663","cik":863894,"company_name":"VERU INC.","ticker":"VERU","form_type":"8-K","filed_at":"2025-12-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Veru reports FY2025 net loss $22.7M, cash $15.8M; enobosarm Phase 2b PLATEAU to start Q1'26","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss from continuing ops $15.7M ($1.07/sh) vs $35.3M ($2.61/sh) prior year; total net loss $22.7M ($1.55/sh).","Post year-end public offering net proceeds ~$23.4M; cash as of Sep 30, 2025 was $15.8M vs $24.9M prior year.","FDA confirmed enobosarm 3 mg acceptable; incremental weight loss of ≥5% placebo-corrected at 52 weeks acceptable primary endpoint for approval.","Phase 2b QUALITY: enobosarm 3 mg preserved 100% lean mass, reduced physical function decline (≥10% stair climb power) from 44.8% to 17.6% with semaglutide.","Phase 2b PLATEAU of enobosarm 3 mg + GLP-1 RA in 200 obesity patients starts Q1 2026; interim results Q1 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":33870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131584,"accession_number":"0001193125-25-258565","cik":863894,"company_name":"VERU INC.","ticker":"VERU","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Veru prices $25.2M public offering of common stock and warrants; net proceeds ~$23.4M for enobosarm study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering includes 1.4M common shares + 7M pre-funded warrants and 8.4M Series A and 8.4M Series B warrants at $3.00/unit.","Gross proceeds expected ~$25.2M; net proceeds ~$23.4M after underwriting discounts and expenses.","Closing expected on or about October 31, 2025, subject to customary conditions.","Proceeds primarily to fund Phase 2b PLATEAU clinical study of enobosarm; also for working capital and general corporate purposes.","Series A warrants expire 5 years from issuance; Series B warrants expire 3 years or upon meeting specific clinical milestones and stock price triggers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":33870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148153,"accession_number":"0001437749-25-029912","cik":863894,"company_name":"VERU INC.","ticker":"VERU","form_type":"8-K","filed_at":"2025-09-26T23:59:59+00:00","items":["1.02","9.01"],"status":"ready","headline":"Veru settles $8.8M Onconetix promissory notes for $6.3M cash and preferred stock/warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Outstanding principal under two promissory notes totaled $8,826,155.41 as of September 22, 2025.","Veru accepted a cash payment of $6,326,155.41, 3,125 shares of Series D Convertible Preferred Stock (stated value $1,000/share), and 846,975 warrants.","Settlement Amounts paid on September 24, 2025; Promissory Notes and Forbearance Agreement terminated.","No assurance of future cash proceeds from the preferred stock, warrants, or underlying common shares.","Release of all claims by Veru against Onconetix upon receipt of settlement consideration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":33870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148152,"accession_number":"0001437749-25-027858","cik":863894,"company_name":"VERU INC.","ticker":"VERU","form_type":"8-K","filed_at":"2025-08-27T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Veru regains Nasdaq minimum bid price compliance; delisting risk removed","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on August 26, 2025 confirming compliance with Listing Rule 5550(a)(2).","Original deficiency notice from August 29, 2024; extended compliance period ended August 25, 2025.","Minimum bid price closed with no further action required from Veru.","Stock had failed to maintain $1.00 minimum for 30 consecutive business days prior."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":33870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148151,"accession_number":"0001437749-25-026037","cik":863894,"company_name":"VERU INC.","ticker":"VERU","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Veru Inc. effects 1-for-10 reverse stock split to regain Nasdaq $1 compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split effective 11:59 pm CT on August 8, 2025; shares trade split-adjusted Aug 11.","Shareholders approved split at July 25 special meeting; board selected 1-for-10 ratio.","No fractional shares; shareholders receive cash in lieu; ownership % unchanged except cash.","Reverse split does not change authorized shares or par value ($0.01).","Split intended to meet Nasdaq $1.00 minimum bid price requirement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":33870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148150,"accession_number":"0001193125-25-178463","cik":863894,"company_name":"VERU INC.","ticker":"VERU","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Veru Q3 net loss narrows to $0.50/sh; enobosarm Phase 2b data show lean mass preservation","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss from continuing ops $7.3M ($0.50/sh) vs $10.3M ($0.71/sh) in Q3 2024.","R&D expense $3.0M, down from $4.8M; SG&A $5.0M, down from $5.8M.","Cash $15.0M at June 30, 2025 vs $24.9M at Sep 30, 2024; burn funds clinical programs.","Phase 2b QUALITY: enobosarm 3mg + semaglutide preserved 100% lean mass (p<0.001) and increased fat loss 12% vs semaglutide alone.","Maintenance Extension: enobosarm 3mg monotherapy reduced weight regain by 46% after semaglutide discontinuation."],"consensus_eps_estimate":-0.4335,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":33870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148149,"accession_number":"0001437749-25-023521","cik":863894,"company_name":"VERU INC.","ticker":"VERU","form_type":"8-K","filed_at":"2025-07-25T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Veru shareholders approve reverse stock split at ratio of 1-for-2 to 1-for-20","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders voted 98,869,209 for, 7,080,957 against, 1,013,920 abstain on reverse split proposal.","Board will determine final reverse split ratio within 1-for-2 to 1-for-20 range.","Adjournment proposal also approved: 100,083,638 for, 6,212,862 against, 667,586 abstain.","A total of 146,583,920 shares were eligible to vote at the July 25, 2025 special meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":33870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166909,"accession_number":"0001193125-25-115453","cik":863894,"company_name":"VERU INC.","ticker":"VERU","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Veru's enobosarm Phase 2b meets primary endpoint; 71% less lean mass loss with GLP-1","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2b QUALITY study met primary endpoint: 71% relative reduction in lean mass loss with enobosarm + semaglutide vs placebo (p=0.002).","Enobosarm 3mg dose resulted in >99% mean relative reduction in lean mass loss (p<0.001); enobosarm 6mg not more effective.","Enobosarm + semaglutide shifted weight loss composition to fat: 90.6% fat loss vs 68% with placebo (p=0.014 for fat mass loss with 6mg).","Physical function improved: 54.4% relative reduction in proportion with ≥10% decline in stair climb power (p=0.0049) for all enobosarm.","Upcoming catalysts: unblinded safety data and Phase 2b extension topline data expected in Q2 2025; End of Phase 2 FDA meeting planned for Q3 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":33870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184309,"accession_number":"0001437749-25-007742","cik":863894,"company_name":"VERU INC.","ticker":"VERU","form_type":"8-K","filed_at":"2025-03-14T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Veru shareholders approve increase in equity plan shares from 18.5M to 26M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amendment to 2018 Equity Incentive Plan, increasing authorized shares from 18,500,000 to 26,000,000.","All six director nominees (Steiner, Fisch, Rankowitz, Hyun, Lu, Katzovitz) were elected at the Annual Meeting.","Cherry Bekaert LLP ratified as independent registered public accounting firm for fiscal year ending Sep 30, 2025.","Broker non-votes totaled 40,992,821 shares on the equity plan and director election matters."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":33870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184308,"accession_number":"0001193125-25-042467","cik":863894,"company_name":"VERU INC.","ticker":"VERU","form_type":"8-K","filed_at":"2025-02-28T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Veru receives Nasdaq extension to Aug 25, 2025 to regain $1.00 bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq granted Veru additional 180 days, until August 25, 2025, to meet minimum $1.00 closing bid price requirement.","Company intends to cure deficiency via reverse stock split if necessary.","If compliance not achieved by Aug 25, 2025, Nasdaq will initiate delisting; company may appeal.","No immediate effect on listing; common stock continues trading on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":33870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184307,"accession_number":"0001193125-25-025576","cik":863894,"company_name":"VERU INC.","ticker":"VERU","form_type":"8-K","filed_at":"2025-02-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Veru reports Q1 net loss $8.9M; positive Phase 2b enobosarm data; FC2 business sold for $18M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss from continuing ops $1.8M ($0.01/sh) vs $7.7M; overall net loss $8.9M ($0.06/sh) vs $8.3M.","R&D expenses rose to $5.7M from $1.7M; SG&A fell to $5.2M from $6.7M; cash $26.6M at Dec 31, 2024.","Phase 2b QUALITY study met primary endpoint: 71% relative reduction in lean mass loss (p=0.002) with enobosarm+semaglutide.","Enobosarm 3mg+semaglutide preserved 99% of lean mass; 62% relative reduction in stair climb power decline (p=0.0066).","Sold FC2 Female Condom business for $18M; net proceeds ~$12.3M; $9.9M liability extinguished."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":33870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184306,"accession_number":"0001437749-25-000208","cik":863894,"company_name":"VERU INC.","ticker":"VERU","form_type":"8-K","filed_at":"2025-01-03T23:59:59+00:00","items":["1.01","1.02","2.01","2.04","8.01","9.01"],"status":"ready","headline":"Veru Inc. sells FC2 female condom business for $18M, netting ~$12.5M after change-of-control payment","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Sold FC2 female condom business to Clear Future, Inc., for $18M cash, subject to working capital adjustment.","Net proceeds to Veru approximately $12.5M after $4.2M change-of-control payment to SWK Funding LLC.","Royalty Agreement with SWK terminated upon payment; related $9.9M liability extinguished.","Headcount reduced by ~90% (from 210 to 22) as Veru focuses on biopharmaceutical pipeline.","Topline results from Phase 2b enobosarm weight loss trial expected in January 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":33870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216896,"accession_number":"0001193125-24-222901","cik":863894,"company_name":"VERU INC.","ticker":"VERU","form_type":"8-K","filed_at":"2024-09-20T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Veru amends forbearance with Onconetix; extends note maturities, adjusts payment terms","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Veru entered amended forbearance agreement with Onconetix for two promissory notes totaling $10M principal.","Forbearance period for April 2024 note extended to March 31, 2025; September 2024 note maturity extended to June 30, 2025.","Interest accrues at 10% per annum on unpaid balances from specified dates.","Payment terms increased: 25% of monthly cash receipts and 20% of net financing proceeds.","If both notes fully repaid in cash by Dec 31, 2024, September 2024 note principal reduced from $5M to $3.5M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":33870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216895,"accession_number":"0001193125-24-211075","cik":863894,"company_name":"VERU INC.","ticker":"VERU","form_type":"8-K","filed_at":"2024-08-30T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Veru receives Nasdaq minimum bid price deficiency notice; 180-day cure period until Feb 25, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Veru on Aug 29, 2024 that common stock bid price was below $1.00 for 30 consecutive business days.","Company has 180 calendar days, until Feb 25, 2025, to regain compliance by closing at $1.00+ for 10 consecutive days.","If not compliant by Feb 25, 2025, Veru may qualify for a second 180-day period if it meets other listing standards and intends to cure via reverse stock split.","Failure to regain compliance could lead to delisting from Nasdaq Capital Market.","Trading of VERU common stock continues unaffected during the cure period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":33870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216894,"accession_number":"0001193125-24-206171","cik":863894,"company_name":"VERU INC.","ticker":"VERU","form_type":"8-K","filed_at":"2024-08-23T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Veru terminates $75M ATM equity agreement with Jefferies; $1.1M raised, effective Sept 3","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminated Open Market Sales Agreement with Jefferies LLC effective Sept 3, 2024; no penalties incurred.","Agreement authorized up to $75M in common stock sales; only 1,367,415 shares sold for net proceeds of $1.1M.","Company will not issue any additional shares under this agreement going forward.","Termination removes a potential source of equity capital but avoids further dilution for existing shareholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":33870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216893,"accession_number":"0001193125-24-196459","cik":863894,"company_name":"VERU INC.","ticker":"VERU","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Veru Q3 net rev $4.0M, net loss $0.07; Phase 2b QUALITY study fully enrolled (>150 pts), topline Jan 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net revenue $4.0M (up 21% YoY); operating loss $10.9M vs $13.7M.","Net loss $11.0M ($0.07/sh) vs $12.5M ($0.14/sh) prior year.","Phase 2b QUALITY trial full enrollment >150 patients achieved; topline lean body mass data expected Jan 2025.","Cash $29.2M at June 30, 2024 vs $9.6M at Sept 30, 2023.","Enobosarm aims to preserve muscle during GLP-1 weight loss; extension study data expected Q2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":10229897.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":33870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216892,"accession_number":"0001193125-24-192858","cik":863894,"company_name":"VERU INC.","ticker":"VERU","form_type":"8-K","filed_at":"2024-08-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Veru appoints Loren Mark Katzovitz to Board of Directors, expanding board to seven","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board size increased from 6 to 7 directors, filling the vacancy with Loren Mark Katzovitz.","Katzovitz is an independent director under NASDAQ standards; will serve on Audit and Compensation Committees.","No material arrangements, family relationships, or transactions requiring disclosure identified."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":33870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216891,"accession_number":"0001193125-24-174334","cik":863894,"company_name":"VERU INC.","ticker":"VERU","form_type":"8-K","filed_at":"2024-07-02T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Veru shareholders re-elect all six director nominees at reconvened 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All six nominees elected; Mitchell Steiner received 75.5M votes for, 2.4M withheld.","Lucy Lu received 62.9M votes for (lowest support); 15.0M shares withheld.","No broker non-votes; quorum of 77.9M shares (53.3% of eligible) represented.","Meeting adjourned from June 18 to June 27 to achieve quorum."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":33870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236645,"accession_number":"0001193125-24-165716","cik":863894,"company_name":"VERU INC.","ticker":"VERU","form_type":"8-K","filed_at":"2024-06-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Veru adjourns 2024 annual meeting after failing to obtain quorum","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Only 72,634,840 shares (49.6%) present vs. required 73,190,594.","Shareholders voted 57.4M for, 15.0M against, 216,919 abstain to approve adjournment.","Meeting adjourned to June 27, 2024, at 9:00 a.m. local time for further proxy solicitation.","No other proposals were voted on; meeting lacked quorum for any business."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":33870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236644,"accession_number":"0001193125-24-144951","cik":863894,"company_name":"VERU INC.","ticker":"VERU","form_type":"8-K","filed_at":"2024-05-22T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Veru dismisses RSM as auditor; engages Cherry Bekaert; cites material weaknesses","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["RSM US LLP dismissed as independent auditor on May 16, 2024; no disagreements reported.","Cherry Bekaert LLP appointed as new auditor on May 21, 2024, approved by Audit Committee.","RSM's FY2023 report included a going-concern explanatory paragraph.","Two material weaknesses disclosed: one related to nonrecurring transactions and one to R&D expense estimates, leading to restatements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":33870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236643,"accession_number":"0001193125-24-133757","cik":863894,"company_name":"VERU INC.","ticker":"VERU","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Veru reports Q2 fiscal 2024 net loss $10M, cash $34.7M; enobosarm Phase 2b enrolling","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Fiscal Q2 net revenues $4.1M (down 38% YoY); net loss $10.0M ($0.07/share) vs $33.8M loss ($0.42) prior year.","Cash and equivalents $34.7M at March 31, 2024, up from $9.6M at Sept 30, 2023.","Phase 2b enobosarm+semaglutide weight loss trial actively enrolling; topline results expected end of 2024.","Extension trial to test muscle maintenance after GLP-1 discontinuation; results expected Q2 2025.","Assembled five-MD Scientific Advisory Board for high quality weight loss program."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":6276027.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":33870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236642,"accession_number":"0001193125-24-118157","cik":863894,"company_name":"VERU INC.","ticker":"VERU","form_type":"8-K","filed_at":"2024-04-26T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Veru enters forbearance with Onconetix on $10M notes after default","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Onconetix defaulted on $5M April 2024 note due Apr 19, 2024; Veru forbears until Mar 31, 2025.","Borrower pays $50k upfront, then 15% of certain cash receipts monthly and 10% of net proceeds from financings.","Interest accrues at 10% on unpaid April note balance from Apr 20; Sept note ($5M) due Sep 30, 2024 unchanged.","Total principal $10M; no assurance of recovery; insolvency default provision waived during forbearance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":33870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236641,"accession_number":"0001193125-24-111507","cik":863894,"company_name":"VERU INC.","ticker":"VERU","form_type":"8-K","filed_at":"2024-04-25T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Veru regains Nasdaq minimum bid price compliance; non-compliance remedied","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on April 23, 2024 confirming compliance with Listing Rule 5550(a)(2).","Previously disclosed on Jan 26, 2024 that average closing bid price was below $1.00 for 30 consecutive days.","Non-compliance remedied; Company now meets continued listing standards.","No further action required to maintain Nasdaq listing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":33870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254268,"accession_number":"0001193125-24-048246","cik":863894,"company_name":"VERU INC.","ticker":"VERU","form_type":"8-K","filed_at":"2024-02-28T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Veru receives Nasdaq delisting notice for delayed Q1 10-Q filing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Veru received a Nasdaq deficiency letter for failing to file Q1 FY2024 10-Q (quarter ended Dec 31, 2023) on time.","Company has 60 days until April 22, 2024 to submit a plan to regain compliance with Nasdaq Listing Rule 5250(c)(1).","If plan is accepted, Veru has until August 19, 2024 to file the 10-Q.","No immediate effect on listing or trading of VERU common stock on Nasdaq Capital Market.","Veru states it is working diligently to complete and file the 10-Q as promptly as possible."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":33870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254267,"accession_number":"0001193125-24-037535","cik":863894,"company_name":"VERU INC.","ticker":"VERU","form_type":"8-K","filed_at":"2024-02-15T23:59:59+00:00","items":["4.02"],"status":"ready","headline":"Veru restates FY2023 financials for R&D expense overstatement; cash runway extends","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit committee concludes FY2023 financials cannot be relied upon due to overestimated R&D expenses.","Overestimation of R&D costs results in cash on hand expected to last longer than previously stated.","Company evaluating impact on FY2022 audited financials and interim quarters of FY2022 and FY2023.","Veru intends to file amended periodic reports; discussed with auditor RSM US LLP."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":33870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254266,"accession_number":"0001193125-24-027504","cik":863894,"company_name":"VERU INC.","ticker":"VERU","form_type":"8-K","filed_at":"2024-02-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Veru reports Q1 revenue $2.1M, cash $40.6M; FDA clears IND for enobosarm with GLP-1 for weight loss","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $2.1M (down from $2.5M YoY); gross profit $1.2M (up from $0.7M).","Cash $40.6M at Dec 31, 2023, bolstered by $35.2M net proceeds from public offering.","FDA cleared IND for enobosarm in combination with GLP-1 drugs to preserve muscle during weight loss.","Phase 2b obesity study to start by April 2024; top-line results expected by end of calendar 2024.","Enobosarm for metastatic breast cancer funding-dependent; sabizabulin COVID program paused without external funding."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":2140726.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":33870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254265,"accession_number":"0001193125-24-016705","cik":863894,"company_name":"VERU INC.","ticker":"VERU","form_type":"8-K","filed_at":"2024-01-26T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Veru receives Nasdaq deficiency notice for bid price below $1.00; 180-day cure period through July 23, 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Veru on Jan 25, 2024 that its closing bid price was below $1.00 for 30 consecutive business days.","Company has until July 23, 2024 to regain compliance by closing at $1.00 or more for 10 consecutive trading days.","Failure to cure may qualify for an additional 180-day period if other listing standards are met and a reverse stock split is considered.","No immediate impact on trading; stock continues on Nasdaq Capital Market during the cure period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":33870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271744,"accession_number":"0001193125-23-297169","cik":863894,"company_name":"VERU INC.","ticker":"VERU","form_type":"8-K","filed_at":"2023-12-18T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Veru prices public offering of 45.8M shares at $0.72, net proceeds ~$35.2M for enobosarm trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered underwriting agreement for 45,833,333 shares at $0.72/share; gross proceeds ~$33M.","Underwriters' option for 6,874,999 additional shares exercised in full on Dec 15.","Net proceeds expected ~$35.2M after discounts and expenses.","Proceeds primarily fund Phase 2b trial of enobosarm for muscle preservation in obese elderly on GLP-1 agonists.","Offering expected to close Dec 18, 2023; Raymond James and Oppenheimer lead."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":33870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271743,"accession_number":"0001193125-23-294320","cik":863894,"company_name":"VERU INC.","ticker":"VERU","form_type":"8-K","filed_at":"2023-12-13T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Veru amends Lincoln Park equity facility to $50M; unveils enobosarm GLP-1 combo plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amended Lincoln Park agreement reduces registered shares from $100M to $50M until $50M sold; only $3.1M sold to date.","Plans to develop enobosarm to augment fat loss and prevent muscle loss in elderly on GLP-1 drugs.","Updated corporate presentation includes enobosarm Phase 2b trial design for sarcopenic obese/overweight patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":33870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271742,"accession_number":"0001193125-23-277950","cik":863894,"company_name":"VERU INC.","ticker":"VERU","form_type":"8-K","filed_at":"2023-11-15T23:59:59+00:00","items":["4.02"],"status":"ready","headline":"VERU restates Q3 FY2023 results; recognizes material weakness, going concern doubt","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gain on sale of ENTADFI assets overstated by ~$12.7M; corrected gain is $4.7M.","$14M in notes receivable improperly recorded; should not have been recognized due to collectability uncertainty.","Company concludes substantial doubt about its ability to continue as a going concern.","Material weakness identified in internal controls over nonrecurring transaction accounting.","Prior June 30, 2023 financials should no longer be relied upon; amended 10-Q/A to be filed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":33870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271741,"accession_number":"0001193125-23-249207","cik":863894,"company_name":"VERU INC.","ticker":"VERU","form_type":"8-K","filed_at":"2023-10-02T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Veru amends asset purchase deal; accepts $1M cash + convertible preferred for $4M note from Blue Water Biotech","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["September 29, 2023: Veru deemed $4M promissory note satisfied by $1M cash and 3,000 shares of Blue Water Biotech Series A Convertible Preferred.","Preferred stock has $1,000 stated value per share, convertible after one year into ~5.7M common shares at $0.5254/share, subject to shareholder approval.","Veru received $1M cash on Sept 29; preferred shares to be issued by Oct 3. Buyer must seek shareholder approval by Dec 31, 2023.","Amendment modifies April 2023 asset purchase agreement; Veru's risk includes future defaults and ability to monetize preferred shares.","Blue Water Biotech (formerly Blue Water Vaccines) issued preferred with redemption rights at buyer's option, no holder redemption rights."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":33870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":288598,"accession_number":"0001193125-23-231951","cik":863894,"company_name":"VERU INC.","ticker":"VERU","form_type":"8-K","filed_at":"2023-09-11T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Veru reports Phase 3 ARTEST data: enobosarm monotherapy shows 12.5% ORR vs 0% control in metastatic breast cancer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Enobosarm monotherapy achieved 2 PR/16 (12.5%) ORR vs 0 PR/18 for active control in discontinued Phase 3 ARTEST trial.","In patients with ≤3 prior endocrine therapies and ≤1 prior CDK4/6 inhibitor, ORR was 33.3% (2/6) vs 0% control.","Enobosarm was well tolerated with no masculinizing AEs or hematocrit increases.","Trial discontinued to focus on earlier-line ENABLAR-2 Phase 3 study of enobosarm + abemaciclib."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":33870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":288597,"accession_number":"0001193125-23-208059","cik":863894,"company_name":"VERU INC.","ticker":"VERU","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Veru Q3 net income $6.3M on ENTADFI gain; pipeline updates for enobosarm, sabizabulin","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income $6.3M ($0.07/diluted share) vs net loss $22.2M ($0.28) in Q3 2022; revenue $3.3M down from $9.6M.","Cash burn reduced to $7.3M in Q3, down $16.1M from prior quarter; cash $16.2M at June 30, 2023.","Sold ENTADFI for $20M in April 2023; potential $80M in sales milestones. Gain of $17.5M recognized.","FDA agrees on Phase 3 ENABLAR-2 design; ORR endpoint in Stage 1 may support accelerated approval for enobosarm in metastatic breast cancer.","Plans to expand sabizabulin Phase 3 confirmatory study to all viral lung infections; FDA meeting scheduled for September 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":12434946.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":33870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":288596,"accession_number":"0001193125-23-197705","cik":863894,"company_name":"VERU INC.","ticker":"VERU","form_type":"8-K","filed_at":"2023-07-28T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Veru shareholders approve doubling authorized common stock to 308M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders voted 62,042,114 for, 3,935,354 against to increase authorized shares from 154M to 308M.","Special meeting held July 24, 2023; 89,236,732 shares eligible to vote.","Articles of Amendment filed with Wisconsin Department of Financial Institutions on July 24, 2023.","Adjournment proposal also approved with 61,372,471 votes in favor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":33870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309161,"accession_number":"0001193125-23-143520","cik":863894,"company_name":"VERU INC.","ticker":"VERU","form_type":"8-K","filed_at":"2023-05-12T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Veru enters into $75M ATM equity offering agreement with Jefferies","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered Open Market Sale Agreement with Jefferies to sell up to $75M of common stock in at-the-market offerings.","Jefferies receives 3% commission on gross proceeds; company also reimburses specified expenses.","Company has ~39.6M shares authorized, unissued, and available; intends to seek shareholder approval to increase authorized shares.","Shares sold under existing Form S-3 shelf registration effective April 14, 2023, and prospectus supplement filed May 12, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":33870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309160,"accession_number":"0001193125-23-141365","cik":863894,"company_name":"VERU INC.","ticker":"VERU","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Veru Q2 net loss $38.8M ($0.48/share); revenue falls to $6.6M; FDA agrees on sabizabulin Phase 3 design","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $38.8M vs $14.2M YoY; operating loss $39.4M including $3.9M impairment and $3.9M credit loss provision.","Revenue down to $6.6M from $13.0M; gross profit $4.1M vs $11.2M; R&D expense rose to $22.9M.","Cash and equivalents $23.5M at March 31, 2023, down from $80.2M at September 30, 2022.","FDA agreed on confirmatory Phase 3 trial for sabizabulin in COVID-19 ARDS; 408-subject, two interim efficacy analyses planned.","Sold ENTADFI for $20M plus up to $80M milestones; Lincoln Park Capital committed up to $100M common stock purchase."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.94,"consensus_revenue_estimate":null,"consensus_revenue_actual":9093761.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":33870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309159,"accession_number":"0001193125-23-133437","cik":863894,"company_name":"VERU INC.","ticker":"VERU","form_type":"8-K","filed_at":"2023-05-03T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Veru signs $100M common stock purchase agreement with Lincoln Park Capital","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $100M of common stock over 36 months; regular purchases ≤225,000 shares/day.","Larger purchases possible at higher stock prices; purchase price based on VWAP or closing price.","Commitment fee of 800,000 shares upfront; additional $1M shares at $50M cumulative purchases.","Exchange cap 17,678,502 shares (19.99% of outstanding) unless shareholder approval or price >$1.26.","Proceeds to be used for working capital and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":33870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309158,"accession_number":"0001193125-23-107340","cik":863894,"company_name":"VERU INC.","ticker":"VERU","form_type":"8-K","filed_at":"2023-04-20T23:59:59+00:00","items":["1.01","2.01","9.01"],"status":"ready","headline":"Veru sells ENTADFI assets to Blue Water Vaccines for $20M upfront + up to $80M milestones","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Asset purchase closed April 19, 2023; buyer paid $6M at closing, owes $4M in FY2023 and $10M in FY2024.","Potential milestone payments of $10M/$20M/$50M if annual net sales reach $100M/$200M/$500M.","Buyer assumed 6% royalty on ENTADFI sales and up to $22.5M in milestone obligations from Camargo agreement.","Veru sold substantially all ENTADFI assets, including IP, regulatory approvals, inventory, and contracts.","Deal shifts Veru's focus away from ENTADFI; milestone payments uncertain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":33870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309157,"accession_number":"0001193125-23-099796","cik":863894,"company_name":"VERU INC.","ticker":"VERU","form_type":"8-K","filed_at":"2023-04-13T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Veru Inc. raises $5M via private placement of 5M shares at $1.00 to Frost Gamma Investments Trust","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 5,000,000 shares of common stock at $1.00 per share to Frost Gamma Investments Trust for total proceeds of $5,000,000.","Shares sold in private placement under Section 4(a)(2)/Rule 506; unregistered and subject to transfer restrictions.","Company will file a resale registration statement within 45 days and maintain effectiveness until third anniversary or full sale.","Purchaser represented as accredited investor; shares fully paid and nonassessable.","Agreement includes customary representations, warranties, and registration rights."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":33870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309156,"accession_number":"0001193125-23-098370","cik":863894,"company_name":"VERU INC.","ticker":"VERU","form_type":"8-K","filed_at":"2023-04-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Veru's contract with largest FC2 customer The Pill Club terminated after payment default","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["The Pill Club accounted for 44% of Veru's net revenues in fiscal 2022 and 43% in 2021.","Veru has $3.9M in accounts receivable from The Pill Club, including $1.3M past due.","The Pill Club refused a binding shipment on March 29; contract auto-terminated after uncured default.","California AG settlement with The Pill Club may further impair its ability to purchase FC2.","Future FC2 revenue from The Pill Club expected to be substantially reduced or eliminated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":33870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":327922,"accession_number":"0001193125-23-087210","cik":863894,"company_name":"VERU INC.","ticker":"VERU","form_type":"8-K","filed_at":"2023-03-31T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Veru shareholders elect all six director nominees, ratify RSM as auditor, approve say-on-pay on triennial basis","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All six director nominees elected; Steiner received 29.2M for, 1.5M withheld; broker non-votes 24.0M.","Shareholders ratified RSM US LLP as auditor for FY2023 with 53.8M votes for, 0.8M against.","Non-binding say-on-pay approved with 23.8M for, 6.4M against.","Shareholders voted for triennial say-on-pay frequency (19.4M votes); board adopts every three years, next vote in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":33870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":327921,"accession_number":"0001193125-23-069935","cik":863894,"company_name":"VERU INC.","ticker":"VERU","form_type":"8-K","filed_at":"2023-03-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Veru refocuses on sabizabulin for COVID/influenza; terminates prostate cancer trial, pauses two assets","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminating Phase 3 VERACITY trial of sabizabulin in prostate cancer; pausing Phase 2 Veru-100 and zuclomiphene development.","Plans Phase 3 confirmatory study of sabizabulin for hospitalized moderate/severe COVID-19 patients at high risk for ARDS.","Plans Phase 3 study of sabizabulin for hospitalized influenza patients at high risk for ARDS.","Updated Phase 3 ENABLAR-2 study of enobosarm + abemaciclib for second-line metastatic breast cancer; rolling ARTEST into it pending FDA/Lilly approval.","Cash conservation measures including personnel reduction; prior FDA denial of EUA for sabizabulin on March 2, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":33870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":327920,"accession_number":"0001193125-23-029167","cik":863894,"company_name":"VERU INC.","ticker":"VERU","form_type":"8-K","filed_at":"2023-02-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Veru reports Q1 FY2023 net loss of $36.8M; revenue falls 82% to $2.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenues decreased to $2.5M from $14.1M in prior-year quarter; gross profit fell to $0.7M.","Net loss of $36.8M ($0.46 per share) vs. $6.4M ($0.08) a year ago; operating loss $35.6M.","Cash and equivalents dropped to $46.9M at Dec 31, 2022 from $80.2M at Sep 30, 2022.","Sabizabulin for COVID-19 under review by FDA, EMA, MHRA, TGA, Health Canada and others.","IDWeek data: sabizabulin showed 81.2% relative reduction in deaths in WHO 4 subset (p=0.0090)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":2507794.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":33870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":345582,"accession_number":"0001193125-22-297978","cik":863894,"company_name":"VERU INC.","ticker":"VERU","form_type":"8-K","filed_at":"2022-12-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Veru reports FY2022 net loss $83.8M; sabizabulin EUA faces FDA advisory panel 8-5 vote against","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year net loss $83.8M ($1.05 diluted EPS) vs net income $7.4M in FY2021.","Total net revenues fell to $39.4M from $61.3M; FC2 product sales decline cited.","R&D spending surged to $70.6M from $32.7M on sabizabulin and oncology programs.","FDA advisory committee voted 8-5 against sabizabulin EUA; final FDA decision pending.","Cash and equivalents $80.2M at Sept. 30, 2022, down from $122.4M a year earlier."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":33870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":362022,"accession_number":"0001193125-22-217945","cik":863894,"company_name":"VERU INC.","ticker":"VERU","form_type":"8-K","filed_at":"2022-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Veru Q3 net loss $22.2M on 46% revenue decline; sabizabulin EUA under FDA, UK, EMA review","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $22.2M ($0.28 per share) vs $2.7M loss a year ago; revenue $9.6M vs $17.7M.","Sabizabulin EUA submitted to FDA June 2022; UK MHRA granted expedited review; EMA Emergency Task Force reviewing for EU emergency use.","Phase 3 COVID-19 trial showed 55.2% relative reduction in deaths; results published in NEJM Evidence.","ENTADFI (tadalafil/finasteride) commercially launched for BPH; FC2 prescription sales down 50% due to telemedicine customer issues.","Cash and equivalents $100.6M as of June 30, 2022, down from $122.4M at Sep 30, 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":36765721.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":33870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-08-11T23:59:59+00:00|362022"}